Amgen and AstraZeneca's Tezspire Achieves Primary and Key Secondary Endpoints in Phase 3 EoE Trial
Tezspire met all primary and key secondary endpoints in a Phase 3 study for eosinophilic esophagitis, showing 24‑week histologic remission and dysphagia improvement, challenging Dupixent's market lead.